12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Herceptin trastuzumab: Phase III data

Genentech Inc., South San Francisco, Calif.
Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan
F. Hoffmann-La Roche Ltd. (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
Product: Herceptin trastuzumab ( RG597)
Business: Cancer
Molecular target: Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu)...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >